VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Inclusion Criteria: * For patients with pancreatic cancer: * Stage I-III cytologically or histologically-proven pancreatic adenocarcinoma * Cancer confirmed to be surgically resectable, with surgery evaluation with planned resection * Patients may have prior neoadjuvant chemotherapy, but no neoadjuvant chemoradiation * No cancer chemotherapy treatment 2 weeks prior to day 2 of treatment * For patients with metastatic colorectal cancer: * Stage IV histologically-proven colorectal adenocarcinoma * Liver metastasis confirmed to be surgically resectable, with surgery evaluation and planned resection; may have minimal extrahepatic disease that is determined to be resectable * Tumor must be confirmed to be microsatellite stable (MSS); if not already reported at a Clinical Laboratory Improvement Act (CLIA)-certified laboratory, we will be able to perform this at Emory University * No prior immunotherapy * No cancer chemotherapy treatment 2 weeks prior to day 1 of treatment * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Absolute neutrophil count ≥ 1,500 cells/µL * Platelets ≥ 100,000/µL * Hemoglobin ≥ 9.0 g/dL (may receive packed red blood cell \[prbc\] transfusion) * Total bilirubin ≤ 1.5 x the upper limit of normal (ULN) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN * Albumin ≥ 3.0 g/dL * Serum creatinine ≤ 1.5 x ULN * Calculated creatinine clearance of ≥ 50 mL/min * International normalized ratio (IN…